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Tumor Response Kinetics after Schedule-Dependent
Paclitaxel Chemoradiation Treatment for Inoperable Non-
small Cell Lung Cancer: A Model for Low-Dose
Chemotherapy Radiosensitization
Hong Zhang, PhD, MD,* Ollivier Hyrien, PhD,† Kishan J. Pandya, MD,‡ Peter C. Keng, PhD,*
and Yuhchyau Chen, PhD, MD*
Purpose: Poor local disease control remains a major obstacle for
inoperable non-small cell lung cancer (NSCLC) after radiotherapy.
We previously reported results of a phase I/II clinical study based on
preclinical investigations of paclitaxel radiation interactions for
inoperable locally advanced NSCLC, which yielded remarkable
local tumor responses and durable in-field tumor control using
schedule-dependent low-dose paclitaxel for radiosensitization.
Given our unique results, we analyzed the tumor response kinetics
and conducted a statistical modeling of tumor response to charac-
terize this regimen.
Methods and Materials: A total of 104 chest CT scans from 27
patients treated in the clinical trial were evaluated. Tumor volumes
were calculated by three-dimensional measurements of pretreatment
and serial post-therapy CT scans. A nonlinear mixed effects model
was used to model response kinetics.
Results: The average tumor volume reduction at 1 month post-
therapy was 69.9  22.6% (standard deviation), and was 80.6 
17.9% at the last follow-up. The nonlinear mixed effects model
predicts that tumor volume will ultimately shrink by at least 75% for
more than 75% of patients treated by this regimen. The model also
suggests that maximum shrinkage is reached within 2 months after
treatment.
Conclusion: Tumor volume response kinetics revealed a rapid
shrinkage of gross tumors using schedule-dependent pulsed low-
dose paclitaxel radiosensitization. This is contrary to the protracted
tumor regression process observed in radiation alone or other che-
moradiation combinations. Statistical modeling may prove useful in
characterizing and comparing different therapeutic regimens.
Key Words: Lung cancer, Radiosensitization, Radiation, Paclitaxel,
Statistical modeling.
(J Thorac Oncol. 2008;3: 563–568)
Locally advanced non-small cell lung cancer (NSCLC)carries a dismal prognosis. While radiation treatment has
historically been the standard therapy for locally advanced
inoperable NSCLC, the benefit of combining chemotherapy
and radiation has been demonstrated by several randomized
control trials.1–6 Nevertheless, even with combined chemo-
radiation therapy, the 5-year survival rate is less than 25% at
best and the local disease failure rates are disappointing in the
range of 50 to 83%.1–6 It is reasonable to believe that cancer
cannot be cured when local disease is not controlled because
surviving local disease continues to be the viable source for
distant metastasis. Significant attempts have been made to
improve local tumor control by combining radiation with
various chemotherapeutic agents,3,7 or by using 3D conformal
techniques to escalate radiation doses.8–10
For locally advanced NSCLC treated with combined
chemoradiation, radiation dose has historically been lim-
ited to 60 to 66 Gy due to dose-limiting tissues such as the
esophagus and normal lung. This is clearly suboptimal
dose intensity for gross human epithelial tumors. Accord-
ing to Fletcher and Shukovsky,11 the radiation dose re-
quired to control human epithelial tumors of 5 to 15 cm is
about 80 to 100 Gy. For inoperable NSCLC, it has been
suggested that the radiation dose required for a 50%
probability of tumor control is as high as 84.5 Gy.12,13
Pushing radiation dose to such high intensity poses a
significant challenge for radiation technology. Dose esca-
lation beyond 75 Gy for locally advanced disease has not
been easy, even with modern conformal technique and
image-guided radiotherapy.8–10
An alternative strategy to improve local disease control
is radiation sensitization. Several agents have been evaluated
so far with various efficacies.3,7,14–17 We previously pub-
lished a pulsed paclitaxel treatment schedule that took advan-
tage of cell cycle kinetics that was based on the preclinical
investigation of lung cancer cell lines.18,19 Paclitaxel stabi-
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lizes microtubules resulting in G2/M cell cycle arrest (the
most radiosensitive phase of the cell cycle), therefore making
it an ideal radiosensitizer. Our preclinical study also showed
that pulsing paclitaxel every 48 hours offers the maximum
apoptotic effect of lung cancer cell lines.19 Based on the
preclinical study, a phase I/II clinical study that was con-
ducted in our institution used low-dose paclitaxel radiosen-
sitization three times per week for locally advanced NSCLC.
We reported superior in-field gross tumor control (97.6%)
when compared with the average tumor control rate of ap-
proximately 50% using full-dose chemoradiation in patients
with inoperable NSCLC.18,19 We observed rapid tumor re-
gression after the pulsed paclitaxel chemoradiation treatment
with very minimal toxicity.20 This unique clinical observation
influenced our interest in exploring the response kinetics of
gross tumors. Information about tumor regression kinetics
and the statistical modeling of treatment regimens may allow
us to characterize special features of different radiosensitiza-
tion regimens as well as provide prognostic or predictive
information for cancer treatment.
MATERIALS AND METHODS
Phase I/II Clinical Study Using Pulsed Paclitaxel
and Radiation
The phase I/II clinical study design and patient charac-
teristics have been described in detail in previous publica-
tions.18,19 This protocol was reviewed and approved by our
institutional IRB. The clinical study began in 1998 and the
last update was in May 2007. Briefly, patients in the phase I/II
study were treated with low-dose paclitaxel through a 1-hour
intravenous infusion at 15–25 mg/m2 three times a week on
Monday, Wednesday, and Friday. Daily radiation was de-
layed for a minimum of 4 hours to allow for G2/M cell cycle
progression. Thoracic radiation was given at a total dose of
60 to 65 Gy for gross disease (GTV) of primary lung cancer
and grossly involved lymph nodes, and 45 to 57 Gy for
microscopic disease in 1.8 Gy daily fractions for 6 to 7.5
weeks. The treatment schema is shown in Table 1. In general,
radiation portals encompassed GTV with 1.5 to 2 cm margins
along with elective regional lymph nodes. All patients en-
rolled in this study had physical examinations, EKG, pretreat-
ment pulmonary function test, CT of chest and upper abdo-
men, and a complete blood count with differential,
electrolytes, and liver function test. We followed up with
patients at 4 to 6 weeks after completion of treatment, then
every 3 to 4 months thereafter using serial chest CT scans.
Volumetric Evaluation of Tumor Response
CT images in Dicom format were electronically trans-
ferred to a commercial treatment planning system (Soma-
Vision). Using the SomaVision software, GTVs were contoured
manually on serial CT images including serial post-treatment
scans. The volumes of GTVs were calculated by the software.
The primary lesion was contoured in the lung window, and
grossly involved lymph nodes were contoured in the soft tissue
window. The tumor volume was calculated after 2 radiation
oncologists approved the final volumes for all the CT images in
this study to ensure consistency. For images that were not in
Dicom format, the lesions were contoured onto the film and then
the volume was calculated.
Statistical Methods
Tumor characteristics were summarized in terms of
mean, median, standard deviation and frequency for statistical
analyses. A statistical model was developed to describe the
kinetics of tumor volume post-treatment. Because multiple ob-
servations were collected on each individual, we described the
evolution over time of relative tumor volumes using a nonlinear
mixed effects model21 specified as (a) Yij  1  i exp
kitij  i  ij, ij  N0, 2, i  1, . . . , 27, where Yij
denotes the relative tumor volume measured at time tij in the i-th
patient. The parameter i represents the residual fraction of
initial tumor volume, that is, the proportion of the initial tumor
volume that will not be eliminated by the treatment, in the i-th
patient. The parameter ki represents the rate of reduction of the
tumor volume after treatment. In order to keep these parameters
positive, we parameterize i and ki as i  exp(1  i1) and
ki  exp(2  i2), where 1 and 2 are fixed parameters
common to all patients, while i1 and i2 are subject-specific
parameters (random effects) that describe the departure of the
residual fraction and the rate of reduction of tumor volume of the
i-th patient from their population means. We assumed that
i  (i1, i2) was a normally distributed random vector with
mean zero and variance-covariance matrix:   s11 s12s12 s22.
Parameter estimation was conducted using an adaptive
Gaussian quadrature and is reported in Table 2. Likelihood
ratio tests were used to validate hypotheses. The model fitting
was carried out using SAS Nl mixed procedure. Model
assumptions including the normality assumptions, the struc-
ture of equation (a) were carefully checked using fittings of
the regression model (a) to individual kinetics. Prediction
limits for the tumor volume at different time points were
computed from the fitted mixed effects model using computer
simulations.
TABLE 1. Treatment Schema
M T W Th F
Paclitaxel X X X
(AM) (AM) (AM)
XRT X X X X X
(PM) (Anytime after 11AM) (PM) (Anytime after 11AM) (PM)
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RESULTS
Patient and Study Characteristics
Thirty-three patients completed at least 6 out of 7 weeks
of chemotherapy and radiation as protocol dictated. Among
these 33 patients, six died before any follow-up; three died of
metastatic disease, two died of pneumonia, and one died of fetal
hemoptysis. We were able to analyze 104 CT scans from 27
patients for treatment response. Both the treatment planning CT
(pretreatment) and serial follow-up CTs of these patients were
analyzed. All had the first follow-up CT scan at 4 to 6 weeks
postchemoradiation, with the exception of one patient whose
first follow-up CT was obtained 2 months after treatment.
Patient and tumor characteristics are shown in Table 3. All the
patients had inoperable NSCLC. Most of them (24/27) had
either stage IIIA or IIIB disease. Three patients had inoperable
stage I or II disease due to poor pulmonary function.
Tumor Volume Response
Figure 1 demonstrates how the tumor volume was
obtained from serial CT scans. The CT images of a patient
treated by pulsed low-dose paclitaxel chemoradiation serve as
an example of tumor contouring by the investigators in serial
follow-up scans of multiple CT axial slices. CT obtained
prior to treatment demonstrates a right upper lobe lesion in
this patient. One can appreciate the fact that at 1 month after
completion of treatment there was already significant shrink-
age of the tumor. There were few residual volume changes
from 5 to 13 months after treatment.
Figure 2 shows the actual tumor volume changes in
cubic centimeters of each individual patient up to 6 months
after completion of treatment. The initial tumor volumes
varied in size; most tumors measured less than 300 cm3 but a
FIGURE 1. Example of CT images of one patient at various
time points postchemoradiation. Tumor contours are dem-
onstrated in the periphery of the lesions. T  0 demon-
strates a right upper lobe lesion before treatment. T  X mo
demonstrates tumor contours at X months after completion
of chemoradiation treatment.
TABLE 2. Estimates with Standard Error of the Parameters
of the Mixed Effects Model
Parameter Estimate  SE
1 2.05  0.22*
2 0.78  0.14*
s11 0.68  0.28*
s22 0.10  0.11
s12 0.23  0.11
2 0.006  0.001*
*Represents values significant at 5%.
TABLE 3. Patient and Tumor Characteristics for Volume
Response Kinetics
Number of patients evaluated 27
Patient characteristics
Median age (range) 67 (43–87)
Male 12
Female 15
Number of patients with 1
follow-up scans
14
Total scans evaluated 104
Average scans per patient 3.85
Range of follow-up duration in
months
2.1–73.7
Stage of patients
Unresectable I–II 3
IIIa/IIIb 24
Median initial tumor volumes
in mL (range)
263.05 (4.6–2219)
Histology
Adenocarcinoma 9
Squamous cell carcinoma 6
Adenosquamous carcinoma 3
Non-small cell lung cancer,
NOS
9
FIGURE 2. Tumor volume changes in absolute cubic centi-
meters of each individual patient from before treatment
(time  0) to months after completion of chemoradiation
treatment. Some patients had only one or 2 follow-up CTs
post-treatment due to death from distant metastasis.
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few measured more than 400 cm3. Irrespective of the initial
tumor sizes, there is a sharp reduction of tumor volume
within the first month after completion of chemoradiation
treatment. Some patients with large tumors did not have
many follow-up CTs due to death from distant metastasis. On
average, there is an 80.6% (SD  17.9%) tumor volume
reduction at the last follow-up. Remarkably, there is an
average of 69.9% (SD  22.6%) reduction even at 1 month
after chemoradiation.
The nonlinear mixed effects model described in “Ma-
terials and Methods” provides a quantitative description of
the tumor response kinetics for pulsed low-dose paclitaxel
radiosensitization in this cohort of cancer patients. When the
real-time tumor volume response was applied to the statistical
modeling, we found various prediction limits for the tumor
volume as a function of time computed by simulating the
model (Figure 3). These simulations indicate that the major
part of tumor reduction occurs 4 to 6 weeks post-treatment.
This is followed by a plateau residual volume, which is likely
stable postradiation fibrosis. The model suggests that tumor
volume will ultimately shrink by at least 75% for more than
75% of the patients, and that such reduction is accomplished
within 2 months after treatment in most patients. Further-
more, less than 5% of the patients had their tumor volume
reduced by 50% or less.
DISCUSSION
This pulsed low-dose paclitaxel radiosensitization che-
moradiation regimen for locally advanced unresectable
NSCLC has some unique clinical features. The integration of
chemoradiation is schedule-dependent, in that radiation treat-
ment time is deliberately delayed to allow for cell cycle
progression after paclitaxel treatment. The results are quite
remarkable in that the response rate was excellent with a
combined CR and PR of 100%, which contrasts other dosing
schedules of taxane-based chemoradiation that have a re-
sponse rate ranging from 65 to 86%.14–17 Our current inves-
tigation by statistical modeling reveals that the rate of gross
tumor regression was rapid within the first 1 month after
chemoradiation, and that maximum tumor regression is ac-
complished within 2 months after treatment in most patients.
As reported previously, the schedule-dependent pulsed
low-dose paclitaxel radiosensitization regimen for locally
advanced unresectable NSCLC resulted in an overall sur-
vival rate of 40% at 2 years for patients who completed the
protocol treatment.19 At the last update in May 2007, 8 out
of 33 patients were still alive with the longest survival time
of 73.7 months. Overall, only 2 out of the 33 patients who
completed protocol treatment had in-field local failure.
Thirty-one out of 33 patients had durable long-term in-
field tumor control until the time of death or last follow-up,
and 23 patients had evidence of disease progression out-
side of the treatment fields at the time of death.
The tumor response kinetics shown here were dramatic
within the first 4 to 6 weeks after treatment. Such rapid
response kinetics are quite different from the report by
Werner-Wasik et al.,22 who investigated tumor response ki-
netics in patients with inoperable NSCLC treated with radi-
ation or combination chemoradiation. Patient tumor volume
response was evaluated 3 months after the completion of the
treatment. It was found that the tumor volume reduction
post-treatment was a gradual process, a scenario commonly
observed in other human solid tumors after radiation or
chemoradiation treatment. Also, it took approximately 7 to 8
months to reach the nadir of volume reduction. Although the
patients were not evaluated at 1 month after the completion of
treatments like we did in our study, it would not have
changed the result of their observation of slow response
kinetics. It is also important to point out that the treatment
regimen in the Werner-Wasik study was quite heterogeneous.
Among 22 patients evaluated, 17 of them received chemo-
therapy (mostly carboplatin/paclitaxel) in addition to thoracic
radiation, and five patients received radiation alone. Our
treatment was homogeneous in that all patients were treated
in a prospective clinical protocol, thus the rapid response
observed in our study may well represent the unique feature
of the combined pulsed paclitaxel and radiation treatment for
inoperable NSCLC.
The prognostic significance of rapid response to the
treatment shown in our study deserves further investigation.
It has been shown that rapid metabolic response to the
chemotherapy for NSCLC may indicate better outcome.23–25
Therefore, rapid volumetric response to chemoradiation in
NSCLC may be used as a prognostic indicator. Knowing
the response kinetics in certain treatment regimens may
allow us to provide more individualized therapy, such as
the need to add adjuvant therapy in patients demonstrating
slower tumor response.
One may argue that if local control impacts distant
progression, it would be interesting to correlate tumor regres-
sion kinetics with distant progression since the chemotherapy
administered in this study at very low doses would not be
expected to have significant impact on distant control. In this
FIGURE 3. Statistical modeling of the tumor response ki-
netics of pulsed paclitaxel chemoradiation for inoperable
NSCLC. The figure demonstrates various prediction limits for
the tumor volume as a function of time computed by simu-
lating the model up to 5 months. Estimates of the model
parameters and their standard errors are shown in Table 2.
Zhang et al. Journal of Thoracic Oncology • Volume 3, Number 6, June 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer566
regard, impact on survival would be important as well, since
survival of the patients would result from the composite of
local and distant control. To address this question, we have
examined the tumor regression kinetics of each individual in
this study. We were hoping to correlate the tumor response
kinetics of each individual with the survival outcome, local
control, and distant control. By examining each case in the
study, it was interesting to note the overall uniformity of the
tumor response kinetics of all patients treated by this regi-
men. Irrespective of the differences in the initial tumor size,
all tumors regressed most rapidly within the first 4 weeks
after completion of chemoradiotherapy. Most tumors demon-
strated regression of approximately 80% (80.6  17.9%) of
the original volume, and the overall in-field tumor control
was 97.6% for all. Thus, the response kinetics did not seem to
have an impact on the survival or distant metastasis due to the
very similar tumor response kinetics of all tumors in this
study. We, however, did find that “larger” initial tumors
developed distant metastasis earlier. The observation that
larger tumors have higher rates of distant metastasis has long
been recognized for NSCLC in the literature. This finding
points to the unique feature of the pulsed-paclitaxel chemo-
radiation treatment in that the tumor response kinetics seems
similar in most individuals treated by this regimen irrespec-
tive of the initial tumor size. Initial tumor size, not the
kinetics of tumor shrinkage, affected the rate of distant
metastasis and survival on an individual basis.
Our study showed somewhat better, if not comparable,
overall survival than most large randomized trials using
combined chemoradiation.14–17 It seems that the superior and
durable in-field tumor control did not translate proportionally
into increased survival. Most patients died of systemic dis-
ease as a result. Effective local disease control may prevent
the treated area from becoming a source of systemic spread
yet locally advanced NSCLC likely has distant micrometas-
tasis at the time of chemoradiotherapy. Our results support
the addition of full-dose chemotherapy to target distant me-
tastasis in addition to achieving maximal local tumor control
in the management of locally advanced NSCLC.
In summary, the statistical modeling of this study
demonstrates the unique feature of pulsed paclitaxel chemo-
radiation treatment, and has provided further confirmation of
our clinical observation in that schedule-dependent pulsed
low-dose paclitaxel radiosensitization is highly effective in
achieving local disease control in locally advanced NSCLC.
The tumor volume response was rapid in contrast to previous
reports with different treatment regimens. The statistical
analysis clearly supports the clinical observation and provides
parameters that may be useful for comparison to other regi-
mens using similar analysis. The application of statistical
modeling of tumor response deserves investigation in other
clinical studies, which may prove to be informative to char-
acterize treatment regimens, establish the prognostic signifi-
cance of initial tumor volume response, and aid clinical
management decisions in this era of multimodality therapy.
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